In just a few hours, Canada will be the first G7 nation and the second country in the world to legalize recreational adult-use of cannabis. Our focus at Tilray will continue to be developing and manufacturing medical cannabis products in our GMP-certified facility and supplying medical cannabis to tens of thousands of patients in Canada and across the globe.
We’re committed to advancing the scientific knowledge of medical cannabis and the clinical applications of cannabinoids and their potential benefits through our ongoing support for research projects and clinical trials, such as studying the effects of high-CBD formulations on children with pediatric epilepsy (Dravet Syndrome) through Toronto’s Hospital for Sick Children.
Some of our other research initiatives include:
- Post-traumatic stress disorder (PTSD) study with Univ